A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.

An increase in the NLR between baseline and 2–8 weeks or 8–14 weeks showed modestly significant correlation with lack of response (Table 1 D and E) with ORs of 0.47 and 0.29 ( p -values of 0.069 and 0.00096), respectively.

also in 257 other papers